Synonyms: MK0752
Compound class:
Synthetic organic
Comment: MK-0752 is a γ-secretase [1] and Notch pathway inhibitor that was originally intended for the treatment of Alzheimer's disease, but was later redeployed for anti-tumour potential.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
MK-0752 progressed to early stage clinical evaluation in a number of cancer types, but as of January 2021 there were no active trials on ClinicalTrials.gov. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00572182 | MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer | Phase 1 Interventional | Pediatric Brain Tumor Consortium | Merck discontinued support for this study, so further accrual of participants was permanently stopped in 2011. | 3 |
NCT00100152 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) | Phase 1 Interventional | Merck Sharp & Dohme Corp. | ||
NCT01098344 | MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery | Phase 1 Interventional | Cancer Research UK | 2 |